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1. Introduction  
Pulmonary arterial hypertension (PAH) is a multi-factorial, progressive disease with 
substantial mortality and morbidity. Despite recent improvements in treatment, mortality 
associated with PAH remains high, with a two-year survival rate after diagnosis of 
approximately 85% (Thenappan et al., 2007). Although advances in the understanding of 
disease development and treatment have been achieved, the pathogenesis of PAH is still not 
clearly understood (Humbert et al., 2004). Therapeutic options remain limited despite the 
introduction of prostacyclin analogues, endothelin receptor antagonists and 
phosphodiesterase 5 inhibitors within the last 15 years. Moreover, these interventions 
predominantly address the endothelial and vascular dysfunction associated with the 
condition, and thus merely delay the progression of the disease rather than offer a cure 
(McLaughlin et al., 2009a, McLaughlin et al., 2009b).  
PAH is a subset of pulmonary hypertensive syndromes, defined by a resting mean 
pulmonary artery pressure (PAP) >25mmHg, pulmonary vascular resistance (PVR) >3 
Wood units and pulmonary wedge pressure <15mmHg, in the absence of other causes of 
PAH (Archer et al., 1998). PAH is primarily a disease of the small pulmonary arteries, 
characterised by vascular proliferation, remodelling and progressive increases in PVR, 
ultimately leading to right ventricular failure and death (Voelkel et al., 2006).  These 
increases in PVR are attributed in part to endothelial dysfunction resulting in 
vasoconstriction, remodelling of the pulmonary vessel wall and thrombosis in situ 
(Budhiraja et al., 2004). The role of inflammation in the development of PAH has been 
suggested (Voelkel et al., 1998). Inflammatory cells, including macrophages and 
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lymphocytes, are increased in the plexiform lesions of hypertensive pulmonary vessels 
(Tuder et al., 1994). Elevated levels of macrophage inflammatory protein-1a, interleukin-1b 
and interleukin-6 are also found in patients with severe pulmonary hypertension (Humbert 
et al., 1995, Fartoukh et al., 1998). However, the haemodynamic aberrations represent only 
one aspect of PAH such that enhanced proliferation, decreased apoptosis and a shift to 
glycolytic metabolism in pulmonary artery smooth muscle cells, fibroblasts and endothelial 
cells are now recognised as central to the pathogenesis of the disease. The causes and clinical 
consequences of PAH have recently been reviewed by a number of international scientists 
and clinicians (Galie et al., 2009a). While intracellular calcium plays a pivotal role in 
controlling vascular tone and remodelling of the arterial wall, it became of prime interest to 
search for alternative biochemical or pharmacological targets in order to better understand 
the haemodynamic and pathophysiological shifts in the functional properties of this specific 
vascular bed. 
Endothelial dysfunction appears to play an integral role in mediating the vasoconstriction 
and structural changes in pulmonary vasculature (Budhiraja et al., 2004). The endothelium 
releases diverse growth factors, vasoactive compounds and lipidic mediators, which 
regulate the physical and biochemical properties of the pulmonary vessels and affect 
vascular contractility and cell growth, thus modifying distal pulmonary artery resistance 
and compliance (Budhiraja et al., 2004). An altered production of various endothelial 
vasoactive mediators, such as NO, prostacyclin, endothelin-1 (ET-1), serotonin and 
thromboxane, has been increasingly recognized in patients with PAH (Giaid et al., 1993). 
Because most of these mediators affect the growth of smooth muscle cells, an alteration in 
their production may facilitate the development of pulmonary vascular hypertrophy and 
the structural remodelling characteristic of PAH (Galie et al., 2009a). In addition to the 
potential consequences of an imbalance in the endothelial production of various mediators, 
injury to the endothelium may expose the underlying vascular media tissue to diverse 
blood-borne factors that may further promote pathological changes (Galie et al., 2009a, 
Saouti et al., 2010). Endothelial dysfunction may also have adverse consequences on 
pulmonary vascular haemostasis by altering the production of anticoagulant factors. Recent 
reports of genetic mutations in endothelial cells of patients with PAH further underscore the 
role of these cells in disease pathogenesis (Galie et al., 2009a). 
Several studies have demonstrated that Ca2+ sensitizing mechanisms of the contractile 
proteins may also be primed under pathophysiological conditions by various vasoactive and 
lipid mediators and that this Ca2+ sensitization process is involved in hypertension (Uehata 
et al., 1997, Hata et al., 2011). In vascular smooth muscle (VSM), ET-1 has been shown to 
enhance Ca2+ sensitivity through the activation of Rho-kinases and PKC-dependent 
phosphorylation of the 17 kDa myosin phosphatase inhibitor protein (CPI-17) pathways 
(Hersch et al., 2004). Contraction of VSM occurs via two related mechanisms: i) a rise in 
cytosolic calcium concentration ([Ca2+]i) which results in the formation of 
calcium/calmodulin complexes and activation of the myosin light chain kinase (MLCK). The 
activated MLCK in turn phosphorylates the 20 kDa myosin light chain (MLC) (Kimura et al., 
1996), resulting in vascular smooth muscle (VSM) cell contraction;  ii) a second Ca2+-
independent mechanism which requires the activation of Rho-kinase as well as PKC-
dependent phosphorylation of myosin phosphatase inhibitor protein of 17 kDa (so called 
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CPI-17) to maintain tone (Somlyo et al., 2003). The calcium sensitization mechanism occurs 
when an agonist, which stimulates the activation of Rho-kinase or the PKC/CPI-17 pathway, 
results in the inhibition of MLC phosphatase (MLCP) (Uehata et al., 1997, Somlyo et al., 
2003, Kitazawa et al., 2010). Rho-kinase inhibits MLCP activity by phosphorylating the 
myosin-binding subunit of MLCP. Alternatively, CPI-17 phosphorylation also results in an 
inhibition of MLCP activity, which in turn maintains steady state tension in VSM (Somlyo et 
al., 2003, Kitazawa et al., 2010). Hence, CPI–17 de-phosphorylation facilitates relaxation as 
reported previously in bronchial smooth muscle tissues (C. Morin, 2008).  
Omega-6 and omega-3 poly-unsaturated fatty acids (PUFA) such as arachidonic acid (AA), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), respectively, can be 
metabolized by cytochrome P-450 (CYP450) enzymes into several classes of oxygenated and 
hydroxylated metabolites (Funk 2001, Fer et al., 2008). Several of these CYP450-derived 
eicosanoids are also known for their ability to modulate vascular (Roman 2002) and airway 
smooth muscle tone (Morin et al., 2009, Mouchaers et al., 2010). 20-hydroxyeicosatetraenoic 
acid (20-HETE) has been shown to induce relaxation of pulmonary arteries in several species 
including humans (Birks et al., 1997). Meanwhile, epoxyeicosatrienoic acid (EET) 
regioisomers have been shown to activate large conductance calcium-activated potassium 
channels in vascular smooth muscle cells and are considered as leading candidates for 
endothelium-derived hyperpolarizing factor (EDHF) in the coronary and systemic 
circulation (Zeldin et al., 1996, Fisslthaler et al., 1999, Node et al., 1999, Capdevila et al., 
2000). Specific CYP450 epoxygenase isoforms are involved in EPA metabolism and produce 
17(18)-epoxyeicosatetraenoic acid (17(18)-EpETE, see Fig.1B) (Lauterbach et al., 2002, 
Nguyen et al., 1999, Schwarz et al., 2004). Epoxy-docosapentaenoic acids are CYP450-
dependent DHA metabolites (Fig. 1C) (Fer et al., 2004, Arnold et al., 2010, Lucas et al., 2010) 
and recent studies have demonstrated that these metabolites display potent vasodilatory 
activities on coronary arteries (Konkel et al., 2011, Wang et al., 2011). Metabolic pathways 
and chemical structures of CYP450-dependent AA, EPA and DHA metabolites known to 
modulate vascular tone are illustrated in Figure 1 A-C. Recently, pharmacological inhibitors 
of CYP450 epoxygenases and hydroxylases, such as N-methylsulfonyl-6-(2-
propargyloxyphenyl)-hexanamide (MS-PPOH) and Dibromo-dodecenyl-methylsulfimide 
(DDMS), were developed to assess the specific role of these metabolites in cardiovascular 
circulation (Nithipatikom et al., 2006).  
In this chapter, we will summarize the role and the effect of 6 CYP-450 metabolites, such as 
EET regioisomers and 20-HETE, as well as their putative involvement in the control of 
pulmonary arterial tone. Moreover, we will review recent reports regarding the mode of 
action of epoxy-3 derivatives, such as EpETE and EpDPE, on pulmonary arteries. 
Although some progress has been made for the diagnosis and treatment of PAH, more 
effective treatments need to be developed. The omega 3 polyunsaturated fatty acids (n-3 
PUFA) have recently attracted much attention in various research fields especially in 
cardiovascular research (McLaughlin et al., 2009a). Accordingly, we will summarize the 
effect of a new DHA-derivative on human pulmonary arteries. Potential involvement of this 
DHA derivative as a novel and prospective medicinal compound will be discussed as 
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Fig. 1. Omega-3 and omega-6 metabolites produced by CYP450 enzymes in lung tissues.  
A: CYP450 epoxygenase and -hydroxylase enzymes metabolize arachidonic acid into two 
major active compounds:   epoxyeicosatrienoic acid (EET) and 20-hydroxyeicosatetraenoic 
acid (20-HETE), respectively. MS-PPOH and DDMS are known specific inhibitors of CYP450 
enzymes.  B: 17,18-epoxyeicosatetraenoic acid (17,18-EpETE) is the major active metabolite 
produced by the action of CYP450 epoxygenase enzymes on eicosapentaenoic acid (EPA).  
C: docosahexaenoic acid (DHA) serves as a substrate for CYP450 epoxygenase enzymes to 
induce the formation of 19,20-epoxy docosapentaenoic acid (19,20-EpDPE).  
2. Role of CYP450-dependent arachidonic acid metabolites in pulmonary 
arteries 
Arachidonic acid is metabolized via cyclooxygenases, lipoxygenases, and cytochrome P-450 
(CYP) enzymes to generate a range of bioactive eicosanoids.  CYP enzymes, with an 
important role in cardiovascular function, are epoxygenases of the CYP2C and 2J gene 
families, which form four regioisomeric epoxyeicosatrienoic acids (5,6-, 8,9-, 11,12-, and 
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14,15-EET) and the -hydroxylases of the CYP4A family, which generate 
hydroxyeicosatetraenoic acids (19- and 20-HETE) (Roman,. 2002).  
In the systemic vasculature, EETs are most commonly described as vasodilators. The 
mechanism of EET-induced vasodilation has been studied extensively and is dependent on 
the hyperpolarisation of vascular smooth muscle cells (Gebremedhin et al., 1992, Hecker et 
al., 1994, Campbell et al., 1996, Eckman et al., 1998, Morin et al., 2007a) resulting from EET-
induced opening of smooth muscle cell potassium channels (Campbell et al., 1996, Zou et 
al., 1996, Eckman et al., 1998, Gebremedhin et al., 1998, Hayabuchi et al., 1998, Morin et al., 
2007a). Although EETs also reduce tension in non-resistant extralobar pulmonary artery 
(PA) segments (Stephenson et al., 1998, Stephenson et al., 2003), all four EET regioisomers 
have been observed to be vasoconstrictors in small-diameter intralobar PA segments in 
rabbits and rats (Yaghi et al., 2001, Zhu et al., 2000). Because EETs also increase vascular 
resistance (and decrease compliance) in isolated perfused rabbit lungs (Stephenson et al., 
2003), the predominant activity of EETs in lung vessels appears to be vasoconstriction. These 
data are supported by the observation that inhibition of epoxygenase activity with specific 
pharmacological inhibitors attenuates PA tension to phenylephrine (Zhu et al., 2000a), 
suggesting that endogenous EETs participate in -adrenergic contraction of the pulmonary 
vasculature.  Zeldin and co-workers reported that the most abundant EET regioisomer 
formed in the rabbit lung was 5,6-EET (Zeldin et al., 1995). Of the four EET regioisomers, 
5,6-EET is also the most potent, albeit labile, constrictor of rabbit pulmonary arteries (Zhu et 
al., 2000b). The 5,6-EET-induced contraction of rabbit PA requires intact endothelium, 
cyclooxygenase activity, and activation of the thromboxane/endoperoxide (TP) receptor 
(Zhu et al., 2000b, Stephenson et al., 2003). Moreover data suggest that 5,6-EET induces 
contraction in intralobar PA by increasing Rho-kinase activity, thus phosphorylating MLC 
and increasing Ca2+ sensitivity of the contractile apparatus in rabbit lung (Losapio et al., 
2005).  
On the other hand, 20-hydroxyeicosatetraenoic acid (20-HETE), a CYP-450 4A metabolite of 
arachidonic acid, constricts renal, cerebral, coronary and mesenteric arteries via inhibitory 
effects on Ca2+-activated K+ channels, increased Ca2+ entry and modulation of Rho-kinase 
activity (Roman,  2002, Randriamboavonjy et al., 2003). However, 20-HETE has been shown 
to be an eicosanoid product of human lung tissue that acts as a potent vasodilator of isolated 
pressurized pulmonary arteries (Birks et al., 1997, Morin et al., 2008). Furthermore, 
cytochrome P-450 4A (CYP4A) protein is expressed in the pulmonary vasculature, a finding 
based on Western blots of PA microsomes (Zhu et al., 1998), the conversion of arachidonic 
acid into 20-HETE by dispersed vascular smooth muscle cells (Zhu et al., 1998), and 
immunohistochemistry localizing CYP4A to rabbit pulmonary capillary endothelium 
(Roman et al., 1993). These observations raise the possibility that products of CYP4A may 
contribute to the control of PA tone. However, the role of 20-HETE or other P-450 
metabolites of AA in pulmonary circulation is not completely understood. In the acute 
hypoxic vasoconstrictive response in isolated blood-perfused rabbit lungs, 20-HETE was 
shown to relax rabbit PA rings, while an inhibitor of 20-HETE synthesis, DDMS, shifted the 
concentration response of PA rings to phenylephrine (PE) to the left, consistent with the loss 
of a pro-relaxing metabolite (Zhu et al., 2000b). Moreover, the inhibition of 20-HETE 
formation by pharmacological agents such as 17-oxydecanoic acid (17-ODYA) and DDMS 
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enhanced the acute hypoxia-induced increase in pulmonary perfusion pressures (Zhu et al., 
2000b).  
In light of these findings, we postulated that, as a vasodilator, 20-HETE may counter 
observed increases in human pulmonary artery (HPA) tone upon serotonin (5-HT) and -
adrenergic stimulations. To perform these experiments, human lung tissues from patients 
undergoing surgery for lung carcinoma and distant from the malignant lesion were 
obtained. Pulmonary arteries of similar weight and length (inner diameter of 0.5 - 0.8 mm) 
were micro-dissected and placed in culture for 24 hours in a humidified incubator at 37C 
under 5% CO2 as previously reported (Guibert et al., 2005, Morin et al., 2008). Resulting data 
demonstrated that 20-HETE acts as a potent vasodilator on HPA pre-contracted with 5-HT 
and phenylephrine (PE) (Figure 2A, Morin C et al., 2008). 20-HETE displayed potent 
relaxing effects on HPA, with IC50 values in the sub-micromolar range ( 0.3 µM) on both 
resting and active tone. In HPA, the relaxing effect induced by 20-HETE was partially 
abolished by 30 % in the presence of iberiotoxin (IbTx) (Morin et al., 2008), suggesting that the 
eicosanoid activates large conducting Ca2+-activated potassium (BKCa) channels which usually 
results in membrane hyperpolarisation. Indeed, microelectrode measurements demonstrated 
that 20-HETE hyperpolarizes human ASM cells, an effect abolished by 10 nM IbTx (Morin et 
al., 2007b). Thus, the mode of action of this compound may be related to its molecular 
interactions with specific ionic channels of the surface membrane, as previously demonstrated 





Fig. 2. Omega-6 -hydroxylase metabolite modulates pulmonary arterial tone.  
A:  Concentration-dependent relaxing responses induced by 20-HETE on distal human 
pulmonary arteries pre-contracted with either 1 µM 5-HT or 1 µM PE. Each point represents 
the mean ± S.E.M. with n=16 and n=14 for each experimental condition, respectively. B: 
Cumulative Concentration Response Curve (CCRC) to free [Ca2+] obtained from β-escin-
permeabilized pulmonary artery rings in control conditions (closed circles, n =16) and in the 
presence of 1 µM 20-HETE (open circles, n = 18). 
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The role of various ion channels in acute and chronic hypoxia in pulmonary vasculature has 
already been described as well (Weir et al., 2006, Guibert et al., 2007). Hence, from a 
physiological standpoint, it is noteworthy to emphasize the relaxing effects displayed by 20-
HETE on both HPA and airway smooth muscle (Birks et al., 1997, Jacobs et al., 1999, Morin 
et al., 2008).  
The inherent Ca2+ sensitivity of the myosin light chain kinase, resulting in MLC 
phosphorylation and contraction and subsequent de-phosphorylation by MLCP, is an 
important mechanism in the regulation of vascular smooth muscle tone (Somlyo et al., 
2003, Koga et al., 2005). Modulation of this mechanism by 20 HETE could explain its 
overall effects on HPA. As shown in figure 2B, 20 HETE significantly reduces Ca2+ 
sensitivity in permeabilized preparations, suggesting that this eicosanoid modulates 
enzymatic systems such as Rho-Kinase and/or PKC/CPI-17 as well as down-stream 
MLCP activity (Morin et al., 2007a). Several studies have suggested that Ca2+ sensitizing 
mechanisms may also be primed under pathophysiological conditions and especially in 
PAH (Uehata et al., 1997, Somlyo et al., 2003). It was therefore of potential clinical interest 
to find a lipid mediator that would be able to shift the Ca2+ activation curve toward higher 
concentrations. Moreover, our group demonstrated that 20-HETE decreases CPI-17 
phosphorylation levels and increase the expression of p116Rip, thus supporting the view 
that this eicosanoid downregulates PKC/CPI-17 and Rho kinase dependent pathways 
(Morin et al., 2008).  
Despite the fact that CYP450 -hydroxylase has been identified in various lung tissues 
(Zeldin et al., 1995, Zhu et al., 1998, Jacob et al., 1999, Roman RJ, 2002, Miyata et al., 2005), a 
key issue has been to demonstrate the endogenous involvement of 20-HETE in human 
pulmonary arteries. Using a pharmacological -hydroxylase inhibitor such as DDMS, (Jacob 
et al., 2006, Nithipatikom et al., 2006) which minimizes the endogenous production of 20-
HETE, it was now possible to amplify tonic responses to various vasoconstrictive agents. 
This experimental strategy enabled us to evaluate the putative role of this eicosanoid in 
human lung vascular tissues. Hence, it was hypothesized that 20-HETE could play the role 
of a paracrine mediator in the HPA wall whereby its basal production would facilitate PA 
dilation and help maintain low blood pressure (12-15 mm Hg) in this specific segment of the 
vascular apparatus. However, the difference in reactivity to 20-HETE between conduit and 
resistance arteries has not been addressed. In fact, 20-HETE is thought to play an important 
role in regulating tone in distal HPA (Diameter < 500 µm). In contrast, consistent 
contractions have been measured and reported in rodents such as guinea pig bronchi 
(Cloutier et al., 2003). Nevertheless, the relaxations induced by 20-HETE may be of 
pharmacological interest in pulmonary arterial hypertension, since it could be used to treat 
this critical clinical condition known to be refractory to classical treatments. Hence it would 
be relevant to analyse the expression of several genes encoding specific proteins, such as the 
CYP450 isoforms in the HPA wall and parenchyma. It has been reported that CYP450 4A 
and other isozymes represent ω-hydroxylases that are responsible for 20-HETE production 
in several human tissues (Gebremedhin et al., 1998), and for which their expression could be 
downregulated in patients diagnosed with PAH (Pierson et al., 2000). This hypothesis lends 
further support to the benefit of studying the functional implication of 20-HETE at both the 
cellular and molecular levels, despite the fact that such studies were initiated some 15 years 
ago in rabbit pulmonary tissues (Zeldin et al., 1995). 
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3. Key role of CYP450 epoxygenase-dependent metabolites derived from EPA 
and DHA in pulmonary hypertension 
It is widely accepted that n-3 PUFA, rich in fish oils, protect against several types of 
cardiovascular diseases such as myocardial infarction, arrhythmia, atherosclerosis, as well 
as hypertension and inflammatory conditions (Abeywardena et al., 2001, Kris-Etherton et 
al., 2002). EPA, DHA or their derivatives may represent active biological components 
mediating these effects. Although the precise cellular and molecular mechanisms 
underlying these beneficial effects are not well understood, the protective effects of PUFA 
are likely related to their direct effects on VSM cells (Mizutani et al., 1997, Hirafuji et al., 
2003). It has been shown that these PUFA activate K+ATP channels and inhibit specific types 
of Ca2+ channels (Ye et al., 2002). These reports suggest that modulation of VSM cell function 
contributes to the beneficial effects of PUFA in the systemic vascular system. EPA may also 
serve as an alternative substrate in CYP450-dependent epoxygenation and hydroxylation 
reactions as shown in rat hepatic and renal microsomes (Van Rollins et al., 1988). The 
CYP450-dependent EPA metabolites include the epoxyeicosatetraenoic acid regioisomers 
5(6)-, 8(9)-, 11(12)-, 14(15)- and 17(18)-EpETE (Lauterbach et al., 2002). Specific CYP450 
epoxygenase isoforms are involved in EPA metabolism which produce (17(18)-EpETE), and 
include CYP1A (Schwarz et al., 2004), CYP4A1, CYP4A3 (Nguyen et al., 1999, Lauterbach et 
al., 2002,) and CYP4A12A. An additional potential source for 17(18)-EpETE are endothelial 
CYP450 isoforms of the 2C and 2J subfamilies that otherwise produce EET from AA. Recent 
studies have demonstrated that EPA epoxides share and even exceed the ability of AA 
epoxides to stimulate large conducting Ca2+-activated potassium (BKCa) channels 
(Lauterbach et al., 2002) and mediate vasodilatation (Zhang et al., 2001a).  
However, several questions remain to be addressed as to the mode of action of EPA 
metabolites in human pulmonary arteries. Our group demonstrated that 17(18)-EpETE 
induced a relaxing effect of smooth muscle from distal human pulmonary arteries (HPA), 
with IC50 values in the sub-micromolar range on both HPA resting and active tone. To our 
knowledge, there are only few publications addressing the effects of 17(18) -EpETE in 
rodents and in cultured VSM cells (Lauterbach et al., 2002, Hercule et al., 2007).  Our data 
showed that the relaxing effect induced by 17(18)-EpETE in HPA under normal external K+ 
concentration was abolished in the presence of IbTx and glyburide (Glyb), suggesting that 
the eicosanoid activates BKCa and KATP channels, hence resulting in membrane 
hyperpolarisation. Indeed, intracellular microelectrode measurements revealed that 17(18)-
EpETE induced significant hyperpolarisation of human pulmonary artery smooth muscle 
cells (Figure 3A). Since IbTx and Glyb prevented these hyperpolarizing effects, thereby 
reducing the relaxation induced by 17(18)-EpETE, BKCa and KATP channel activation thus 
appears to be a key determinant in the control of both HPA membrane potential and tone 
(Figure 3B). Moreover, it has been demonstrated that EPA epoxides share and even exceed 
the ability of AA epoxides to stimulate BKCa channels (Lauterbach et al., 2002) and to 
mediate vasodilatation in canine and porcine coronary microvessels (Zhang et al., 2001a). 
Using patch clamp measurements, 17(18)-EpETE has also been demonstrated to stimulate 
K+ outward currents, displaying typical characteristics for BKCa channel activation in 
systemic VSM cells. Moreover, this effect is abolished by TEA, a BKCa channel blocker 
(Lauterbach et al., 2002). Recently, the BK subunit, the pore-forming subunit of octameric 
BKCa channels, was shown to represent the main molecular target of 17(18) -EpETE in 
systemic VSM cells isolated from rat cerebral and mesenteric arteries (Hercule et al., 2007).  
www.intechopen.com
3 and 6 CYP450 Eicosanoid Derivatives:  
Key Lipid Mediators in the Regulation of Pulmonary Hypertension 91 
 
Fig. 3. EPA-derived metabolite hyperpolarisation of pulmonary arterial smooth muscles.  
A: Recording of the membrane potential from pulmonary artery in control and following 
addition of cumulative concentrations of 17(18)-EpETE. At the end of each recording, the 
microelectrode was removed from the pulmonary artery smooth muscle cell to validate the 
electrophysiological measurements. B: Mean resting membrane potential values determined 
for 1 µM 17(18)-EpETE and following addition of either 10 nM IbTx or 10 nM IbTx plus  
10 µM glyburide. (n = 7 for each condition).  
 
 
Fig. 4. DHA CYP450 epoxygenase metabolite-induced relaxation of pulmonary arterial 
smooth muscle. 
A: Cumulative concentration response curve displaying the mean tension induced by 30 nM 
U46619 in control and after 24h-treatments with increasing concentrations of 19,20-EpDPE 
(0.001-10 µM), n=12 for each experimental condition. 
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CYP450-dependent DHA metabolites include the epoxy-docosapentaenoic acid 
regioisomers 4(5)-, 7(8)-, 10(11)-, 13(14)-, 16(17)- and 19(20)-EpDPE (Fer et al., 2008, Arnold 
et al., 2010, Lucas et al., 2010). Several epoxygenases have been identified in lung tissues, 
including 2J2, 2C8 2C9 and 1B1 (Fer et al., 2008). Recent studies have demonstrated that 
CYP450 epoxygenase metabolites of DHA display potent vasodilatory activities on coronary 
arteries. These epoxy-eicosanoids have been reported to be more potent than EET and EPA 
in activating BKCa channels (Konkel et al., 2011, Wang et al., 2011). In our laboratory, 
experiments were designed to assess the relaxing effect of 19,20-EpDPE on human 
pulmonary arteries pre-contracted with 30 nM U-46619, a TP receptor agonist. HPA were 
cultured for 24 hours in the absence or presence of increasing concentrations of 19,20-
EpDPE. The tissues were then subjected to 0.6 grams of basal tone and thereafter challenged 
with 30 nM U-46619. The cumulative concentration response curve (CCRC) to 19,20-EpDPE 
(0.01-100 µM) revealed a concentration-dependent inhibitory effect on active tone, with an 
EC50 value of 0.11 µM (Figure 4). 
4. Current treatments and new therapeutic strategies using omega-3 
monoglyceride for PAH 
Significant advances in the treatment of PAH have been made in the last 15 years. These 
agents target the prostacyclin pathway, the nitric oxide pathway and the endothelin 
pathway. A number of vasoactive substances are involved in the pathogenesis of PAH, 
including a major imbalance observed between prostacyclin and thromboxane. Both of these 
substances are by-products of arachidonic acid metabolism by endothelial cells. 
Prostacyclins increase intracellular cyclic AMP and reduce intracellular Ca2+ (Clapp et al., 
2002). Transcription factors and cell cycle progression are dependent on [Ca2+]i. 
Prostacyclins also inhibit platelet activation, promote vasodilatation and inhibit smooth 
muscle proliferation. Thromboxane, which is also produced by endothelial cells, antagonizes 
the effects of prostacyclin. The imbalance between prostacyclin and thromboxane may result 
from a combination of genetic factors and aberrant response to certain forms of injury to 
endothelial cells. Intravenous prostacyclin was first introduced in the treatment of primary 
pulmonary arterial hypertension in the early 1980s. A cohort analysis of patients receiving 
intravenous prostacyclin has shown benefits in New York Heart Association (NYHA) class 
III and IV patients with regard to survival (McLaughlin et al., 2002b, Sitbon et al., 2002). In 
addition to idiopathic pulmonary arterial hypertension, epoprostenol has been successfully 
used in the treatment of pulmonary hypertension resulting from left to right shunt, portal 
hypertension and HIV infection (Rosenzweig et al., 1999, Nunes et al., 2003). While 
epoprostenol has shown a definite role in the treatment of primary and other forms of 
pulmonary hypertension, it remains expensive and very cumbersome to use. 
Administration of this medication requires a central line and a pump. Treatment with 
epoprostenol causes several side effects, with central line infection being a serious side effect 
(Palmer et al., 1998, Humbert et al., 1998). Other stable prostacyclins such as Treprostinil 
and Iloprost are also used in the treatment of PAH. However, side effects are similar to 
those exhibited by epoprostenol (Hoeper et al., 2000, Olschewski et al., 2002).  
Endothelin-1 is produced by the vascular endothelium and serves as a vasoconstrictor and 
smooth muscle mitogen. While its action on endothelin-A receptors results in 
vasoconstriction through activation of protein kinase and an increase in [Ca2+]i, its effect on 
endothelin-B receptors results in vasodilatation secondary to prostacyclin and nitric oxide 
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release in addition to aiding in its clearance. Endothelin receptor antagonists are also 
currently used in the treatment of PAH. For example, bosentan is a non-selective endothelial 
receptor antagonist. Endothelin A receptor stimulation results in vasoconstriction and 
smooth muscle proliferation, while endothelin B receptor stimulation results in endothelin 
clearance as well as induction of NO and prostacyclin by endothelial cells. Two randomized 
double-blind placebo-controlled class III and IV trials have evaluated bosentan in patients 
with pulmonary arterial hypertension. Study results showed a significant improvement in 6 
min walk test and haemodynamics in the bosentan group. In addition, an improvement in 
the time to clinical worsening such as death, lung transplantation and hospitalization was 
also noted (Channick et al., 2001, Rubin et al., 2002). Bosentan is metabolized by the liver 
and an increase in transaminases has been noted during treatment with this medication. 
Hence, it is mandatory to perform periodic liver function tests in patients taking bosentan 
and ambrisentan are other examples of selective ETA receptor antagonists. Ambrisentan 
does not seem to have toxic effects on the liver, while bosentan induces hepatotoxicity (Barst 
et al., 2001, Barst et al 2006).  
Often viewed as an endothelial disease, PAH has already been related i) to changes in 
membrane receptor and ionic channel expression (Guibert et al., 2007), ii) to a decrease in 
NO production, due to a lower nitric oxide synthase (NOS) activity (Guibert, 2010), and iii) 
to a downstream decrease in cGMP related to lower guanylate cyclase activity, which in 
turn activates potassium channels and hyperpolarizes VSM cells (Guibert, 2010). This 
process results in an inactivation of Ca2+ channel activity and decreases intracellular free 
Ca2+, leading to vasodilatation. In fact, patients with PAH show impaired NO synthase 
activity. Impaired synthesis of endothelium-derived nitric oxide and enhanced production 
of vasoconstrictor endothelin have also been implicated in the pathogenesis of PAH (Giaid 
et al., 1993, Giaid A et al., 1995).  Nitric oxide treatment is very cumbersome and is mainly 
used in the management of pulmonary hypertension in the neonatal intensive care unit 
(ICU) and occasionally in adult ICU (Giaid et al., 1993). 
High-doses of Ca2+ channel blockers have been shown by uncontrolled studies to prolong 
survival in patients with PAH (Fuster et al., 1984, Rich et al., 1992), with approximately 10% 
of such patients belonging to this group. In a large retrospective study of 557 patients with 
PAH, less than 7% of patients responded to Ca2+-channel blockers. Among these, patients 
who had a significant vasodilator response exhibited a long-term response to Ca2+-channel 
blockers. Long-term therapy with Ca2+-channel blockers is not recommended when there is 
no acute vasodilator response (Fuster et al., 1984). 
Pulmonary vasculature contains substantial amounts of phosphodiesterase type-5 (PDE-5) 
enzyme and inhibition of this enzyme results in vasodilatation through the NO/cGMP 
pathway. Hence, the potential clinical benefit of phosphodiesterase type-5 inhibitors has 
been investigated in PAH (Pauvert et al., 2004). In addition, phosphodiesterase type-5 
inhibitors exert anti-proliferative effects (Galie et al., 2009b). Sildenafil, a PDE-5 inhibitor, 
increases the levels of cyclic GMP in smooth muscle cells and causes vasodilatation. 
Tadalafil is a long acting PDE-5 inhibitor which has also been used in the management of 
PAH. The major landmark trial involving sildenafil was conducted in the pulmonary 
arterial hypertension (SUPER) study. Two hundred seventy-eight patients with functional 
class II–IV PAH were randomized to three different doses of sildenafil, namely 20, 40, or  
80 mg, three times daily or to placebo. The study extended over a period of 12 weeks and, 
based on the convincing results, the FDA subsequently approved a thrice-daily dose of  
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20 mg sildenafil in the treatment of PAH (Galie et al., 2009b).  The PHIRST Trial studied the 
efficacy and safety of the long acting phosphodiesterase-type five inhibitor (PDE 5-I) 
tadalafil. The study extended over a period of 16 weeks and doses of tadalafil used were 2.5, 
10, 20, and 40 mg. Based on the positive responses, the FDA approved the use of tadalafil 40 
mg once a day (Galie et al., 2009b). However these phosphodiesterase-5 inhibitors also 
induce common side effects and, in some cases, quite severe reactions such as sudden 
blindness, myocardial infarction, stroke and sudden cardiac death secondary to ventricular 
arrhythmias have been recognized. 
Hence, despite the introduction of prostacyclin analogues, endothelin receptor antagonists 
and phosphodiesterase 5 inhibitors within the last 15 years, therapeutic options for 
pulmonary hypertension remain limited. To date, these interventions predominantly 
address the endothelial and vascular dysfunction associated with the condition, and thus 
merely delay the progression of the disease rather than offer a cure (McLaughlin et al., 
2009). Clinical assessment of dietary supplementation of omega-3 (n-3) polyunsaturated 
fatty acids (PUFA) including EPA and DHA has shown their beneficial impact in a wide 
range of cardiovascular diseases (Connor, 2000). One explanation for these beneficial effects 
is that n-3 PUFA competes with arachidonic acid (AA) for enzymatic conversion by COX, 
LOX and CYP450 enzymes. This competition can lead to reduced formation of vasoactive 
AA metabolites while alternative PUFA-metabolites originating from DHA and EPA are 
increased. In a recent study, the DHA metabolite 16,17-EpDPE was shown to mediate 
vasodilatation of coronary arteries by the activation of BK channels (Wang et al., 2011). 
These n-3 PUFA effects are also mediated by a variety of mechanisms that involve both 
indirect (by eicosanoids and hormones) and direct genomic effects. In addition, EPA and 
DHA have been reported to reduce the expression of genes for interleukins, vascular cell 
adhesion molecule-1, intracellular adhesion molecule-1, endothelial adhesion molecule and 
E-selectin (Clarke et al., 1993, De Caterina et al., 1994, Tagawa et al., 1999). Recently our group 
has synthesized a new DHA monoglyceride derivative (Figure 5A, Fortin, 2008) in order to 
assess the effect of n-3 PUFA on pulmonary arterial tone and their involvement in key 
components of PAH pathogenesis. Fatty acids in monoglyceride form are generally recognized 
as safe and are widely used as emulsifying agents in the food industry. Pharmacokinetic 
experiments were thus performed on rats treated with an oral dose of 309 mg/kg of either 
DHA monoglyceride (MAG-DHA), DHA triglycerides (DHA-TG) or DHA ethyl ester (DHA-
EE), based on the recommended daily dose of DHA for humans following dose translation 
from human to rat by the equation described by Reagan-Shaw et al., 2008. Blood samples from 
different groups were taken at 0, 0.5, 4, 8 and 24 h post-drug administration and DHA 
concentration (%) in plasma was determined by high performance liquid chromatography 
(HPLC). Figure 5B demonstrates that DHA monoacylglyceride increases the oral 
bioavailability of DHA compared to commercially available marine oil (Fortin, 2008).  
The Rho-kinase pathway participates in vasoconstriction elicited by numerous agents involved 
in PAH, including TXA2, ET-1 and 5-HT (Rodat-Despoix et al., 2009; Rodat-Despoix et al., 
2008; Connolly & Aaronson, 2011). Rho is a small monomeric GTPase which activates Rho-
associated kinase (ROCK) which in turn phosphorylates and inhibits myosin light chain 
phosphatase, leading to prolonged, refractory vasoconstriction. Rho kinase is considered to be 
a major determinant of arterial tone, through its essential role in the regulation of Ca2+ 
sensitivity of the contractile machinery in smooth muscle cells (Somlyo et al., 2003). Moreover, 
Rho kinase regulates a variety of cellular functions including motility, proliferation, apoptosis, 
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contraction and gene expression. Amongst promising targets recently identified is the Rho-
kinase pathway (Loirand et al., 2006). Recent pharmacological studies suggest that activation 
of the small G protein RhoA and its target Rho kinase is a critical shared mechanism in the 
pathogenesis of PAH (Loirand et al., 2006). In vivo, potent effects of treatment with Rho-kinase 
inhibitors (Y-27632 or fasudil) have been demonstrated in several animal models of PAH (Abe 
et al., 2004, Fagan et al., 2004, Nagaoka et al., 2006). Furthermore, acute intravenous 
administration of low dose fasudil has been shown to reduce PVR and Ppa in patients with 
PAH (Fukumoto et al., 2005, Ishikura et al., 2006, Fujita et al., 2010). 
 
Fig. 5. Chemical structure and oral absorption of DHA monoacylglyceride (MAG-DHA).  
A: MAG-DHA was synthesized from highly purified DHA attached to a monoglycerol in sn-1 
position. B: Pharmacokinetic experiments showing DHA concentration (%) in plasma derived 
from rats treated with an oral dose (309 mg/kg) of either DHA triglycerides (TG-DHA), DHA 
monoglyceride (MAG-DHA) or DHA ethyl ester (DHA-EE). Blood samples were taken at 0, 
0.5, 4, 8 and 24 h post-drug administration, (n=6 for each experimental condition). 
To investigate the potential usefulness of MAG-DHA, complementary approaches were 
used in our laboratory to assess putative changes in Ca2+ sensitivity and to determine the 
activation of RhoA in human pulmonary arteries. Comparative analyses were performed on 
β-escin-permeabilized human pulmonary arterial rings to assess the effect of MAG-DHA 
pre-treatments on Ca2+ sensitivity. Figure 6A illustrates CCRC to free Ca2+ concentrations on 
permeabilized HPA rings obtained from control and treated tissues. When compared to 
control (untreated) condition (Fig. 6A, dashed line), addition of the TP receptor agonist U-
46619 to the organ bath enhanced Ca2+ sensitivity to pre-calibrated Ca2+ step increases in 
HPA explants (Fig. 6A, open circles). However, MAG-DHA pretreatment resulted in a 
marked inhibitory effect on Ca2+-sensitivity (right shift) developed by U-46619-treated 
explants. Data analysis demonstrated that MAG-DHA treatment induced a shift in EC50 
values (0.94 µM) toward higher Ca2+ concentrations when compared to untreated tissues 
challenged with U-46619 (0.13 µM) (Fig. 6A). However, the difference in Ca2+ sensitivity 
between control HPA and tissues pre-treated with 3 µM MAG-DHA was not significant, 
with EC50 values of 0.65 µM and 0.51 µM, respectively (Figure 6A). Furthermore, the 
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involvement of the Rho-kinase pathway was examined using a RhoA pull down assay to 
evaluate RhoA activity following MAG-DHA treatment in HPA-derived homogenates. 
Thus, in order to investigate whether these observations were correlated with a modulation 
status of contractile proteins, RhoA activity level was assessed in HPA following MAG-
DHA treatment in the absence or presence of MSPPOH, a CYP450 epoxygenase inhibitor 
and in 19,20-EpDPE-treated tissues alone. Western blot and quantitative analyses of GTP-
RhoA/RhoA ratio revealed that MAG-DHA treatment reduced the activity of RhoA 
induced by U-46619, while an increased RhoA activity level was observed in the presence of 
MS-PPOH. Hence, 19,20-EpDPE pre-treatment resulted in a reduction in RhoA activity level 
when compared to the activity level detected upon U-46619 treatment (Figure 6B). These 
data suggest that MAG-DHA can be metabolized by CYP450 epoxygenase enzymes, leading 
to the sequential production of 19,20-EpDPE. This CYP450 metabolite in turn decreases 
RhoA activity level leading to an inhibition of Rho-kinase activation, thus resulting in a 
lower Ca2+-sensitivity of HPA. 
 
Fig. 6. MAG-DHA modulates Ca2+ sensitivity and Rho A activity in human pulmonary 
arteries.  
A: Cumulative Concentration Response Curve to free [Ca2+] obtained in control (untreated 
HPA) and after short term (20 min) stimulation with 30 nM U-46619; as well as on 3 µM 
MAG-DHA-treated HPA alone and after 30 nM U46619 challenge. Each point represents the 
mean ± s.e.m., n= 12 for each experimental condition, * p < 0.05. B: RhoA activity was 
quantified in human pulmonary artery homogenates by measurement of RhoA-GTP using a 
Rhotekin pull-down assay, (n=8 for each experimental condition, * p < 0.05). 
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Several studies have demonstrated that the use of Rho-kinase inhibitors reduces PAH in 
many animal models (Oka et al., 2007, Mouchaers et al., 2010). Y-27632 inhaled at 10 – 100 
mM was shown to reduce mean pulmonary arterial pressure without altering systemic 
arterial pressure in a hypoxic rat model of hypertension (Nagaoka et al., 2004). In the 
monocrotaline model, fasudil 30 or 100 mg/kg/day per os improved survival, pulmonary 
hypertension, right ventricular hypertrophy as well as pulmonary vascular lesions (Abe et 
al., 2004). In Fawn-hooded rats exhibiting a raised pulmonary arterial pressure (PAP), 
inhaled fasudil reduced PAP to 55 mmHg without altering mean systemic arterial pressure 
(Nagaoka et al., 2006). In humans, Rho-kinase inhibition with fasudil has also been shown to 
bring about an immediate, albeit modest, reduction in PVR, although this Rho kinase 
inhibitor must be administrated by nebulisation to avoid systemic hypotension (Fujita et al., 
2010, Ishikura et al., 2006). Our data attest that MAG-DHA, a newly synthesized DHA 
derivative, targets the Rho-kinase pathway to reduce U-46619-induced tension in HPA. 
Moreover, we were able to demonstrate that MAG-DHA treatment reduced RhoA activation 
which in turn inactivated the Rho-kinase pathway resulting in a reduction in U-46619-
induced Ca2+ sensitivity of human pulmonary arterial smooth muscle cells. Finally, our data 
with the newly synthesized DHA derivative, MAG-DHA, could represent a new 
pharmacological agent of clinical interest in the management of PAH. Further investigations 
using in vivo models, such as a hypoxic rat model or a monocrotaline model of hypertension 
would however be required to determine the efficacy of MAG-DHA per os treatments in 
reversing pulmonary hypertension. Furthermore, the identification of CYP450 epoxygenase 
metabolites using high performance liquid chromatography coupled to tandem mass 
spectrometry (HPLC/MS/MS) may prove useful to explain the effect of MAG-DHA in these 
in vivo hypertension models. 
5. Conclusion 
Long-chain PUFAs are metabolized by CYP450 epoxygenase and -hydroxylase enzymes in 
the lung which induce the production of several bioactive eicosanoids, such as the EET 
regioisomers, 20-HETE, 17,18-EpETE and docosanoids, such as 19,20-EpDPE. These epoxy- 
and hydroxyl-derivatives are able to modulate the electrophysiological and mechanical 
properties of human pulmonary arterial smooth muscle. In addition, these vasoactive 
metabolites induce the activation of K+ channels and reduce the Ca2+ sensitivity of the 
contractile apparatus in preparations derived from human pulmonary arteries. The main 
limitation of these compounds is their relative instability, further justifying the use of 
biochemical precursors or stable analogues (Roman, 2002). Thus we propose that PUFA 
derivatives, possessing selective pulmonary vasodilation capabilities, may provide an 
interesting new approach for various forms of PAH. Moreover, we have evaluated and 
summarized the effects of DHA monoacylglyceride on the reactivity of pulmonary arterial 
smooth muscle. Data revealed that MAG-DHA is likely metabolized into 19,20-EpDPE by 
the action of CYP450 epoxygenases in human lung. This epoxy-metabolite prevents U-
46619-induced vasoconstriction through a decrease in RhoA activation thus leading to a 
reduction in Ca2+ sensitivity of smooth muscle cells. Since the activated RhoA/Rho kinase 
pathway is associated with both acute pulmonary vasoconstriction and chronic pulmonary 
artery remodelling, it is of potential clinical interest to find a lipid mediator able to reduce 
the activation of Rho-kinase. Moreover, animal and clinical studies have demonstrated that 
Rho-kinase inhibitors could inhibit signal transductions initiated by many vasoactive drugs; 
www.intechopen.com
 
Pulmonary Hypertension – From Bench Research to Clinical Challenges 98
hence it is possible that MAG-DHA may exert broader beneficial effects as compared to 
single receptor antagonists due to its mode of action on intracellular targets. In this respect, 
it is postulated that DHA-monoacylglyceride leads to the production of bioactive 
metabolites which represent new and prospective pharmacological compounds of low 
toxicity and medicinal interest in modulating pulmonary vasoconstriction. Collectively, the 
present review provides new insight regarding the mode of actions of specific epoxy and 
hydroxy eicosanoids and docosanoids, which represent biochemical compounds of putative 
clinical relevance in pulmonary hypertension.  
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